Preclinical WebsiteClinical Website

AAV Tauopathy (AAV-Tau) Model Overview

For this model of Progressive Supranuclear Palsy and Corticobasal Degeneration, we perform unilateral stereotaxic inoculation of AAVs overexpressing wild-type human tau (MAPT) into the substantia nigra of C57BL/6 mice at ~2-3 months-of-age. This mouse model reproduces several key features of human tauopathies, including:

  • Reduction of dopaminergic neurons in the substantia nigra pars compacta
  • Dopaminergic denervation of the ipsilateral striatum
  • Aggregates of phosphorylated tau in cell bodies and neurites
  • Activated microglia
  • Reactive astrocytes
  • Motor dysfunction
  • Brain atrophy (substantia nigra, midbrain, caudate-putamen) measured by in vivo MRI scans

AAV-Tau Model Generation

A general schema for the model generation is:

A stereotaxic surgery setup with a rodent

For this specific model, we use C57BL/6 mice at ~8-12 weeks-of-age. We then perform stereotaxic injection of AAV vectors into the vicinity of the substantia nigra. We use digital stereotaxic devices with automated microinjectors for high accuracy & precision.

Studies using this model can be rapidly initiated. The in vivo phase of the study typically lasts approximately 6 weeks. As such, generation of readouts can be provided in a relatively short time frame, especially compared to conventional tau transgenic models of Alzheimer's disease & tauopathies.

Our Validated Measures

  • Hindlimb clasping test
  • Tail suspension swing test
  • Cylinder test
  • Rotarod test
  • MRI brain atrophy
  • IHC & multiplex immunofluorescence

Learn more about the translatability of this model to human tauopathies.

 

AT8 immunofluorescence staining in the injected SNc
Microglia(orange)+Astrocytes(violet)
THSTR B203-TR-L006 RND083S208
TH+LMX1B SN AAVTau
1/4
pause

AT8 immunofluorescence staining in the injected SNc 

Iba-1 and GFAP double immunofluorescence staining in the injected SNc 

Dramatic reduction of tyrosine hydroxylase staining in the ipsilateral hemisphere 

Severe loss of dopaminergic neurons in the injected SNc 

Model Characterization

The Interactive Presentation below allows you to explore our characterization of our AAV-Tau mouse model, including in vivo data and high-resolution images of entire Multiplex Immunofluorescence tissue sections.

You can simply navigate through this "Image Story" using the left panel.

You can pan around the high-resolution microscopy images using the left mouse button. You can zoom in and out using the mouse/trackpad (up/down) or the + and - buttons in the upper left corner. You can toggle (on/off), change color, and adjust image settings for the channels and segmentations in the Control Panel in the upper right corner.

We suggest using Full Screen Mode for the best interactive experience.

Characterization of a Novel AAV-hTau Mouse Model of Tauopathies with Parkinsonian Features

1/14

Biospective Preclinical Logo

Tauopathies, such as Progressive Supranuclear Palsy and Corticobasal Degeneration, are rare diseases with prominent Parkinsonian features, including motor symptoms such as postural instability, vertical gaze palsy, rigidity, slowed movement (bradykinesia), muscle contractions (dystonia), and sudden jerks (myoclonus). Furthermore, individuals may face difficulties with speech and swallowing, cognitive decline, and loss of sensory perception at the cortical level. These neurodegenerative diseases are often rapidly progressing and pathologically characterized by phosphorylated tau inclusions in neurons and glia.

A significant problem for the development of disease-modifying therapeutics for tauopathies is the lack of animal models that recapitulate the human disease. To address this issue, Biospective has developed and characterized an adeno-associated virus (AAV) vector-induced mouse model that is well-suited for preclinical therapeutic efficacy studies for Progressive Supranuclear Palsy and Corticobasal Degeneration.

This Interactive Presentation illustrates some of the key motor function, neuroimaging, and pathologic features of Biospective's AAV human tau model of tauopathies with Parkinsonian features.

This model was generated by injecting 2 month-old C57BL/6 mice with AAV-hTau (wild-type 2N4R human tau) or AAV-null (control) vectors unilaterally into the left substantia nigra pars compacta (SNc) using a digital stereotaxic device with an automated microinjector.

Coronal Atlas with AAV Injection Site

Coronal Atlas View of SNc Injection Site

Multiplex immunofluorescence (mIF) images were generated by immunostaining for phosphorylated Tau (AT8), GFAP, Iba-1, Tyrosine Hydroxylase, Dopaminergic Nuclei, and counterstained with the DAPI nuclear stain. Tissue sections were digitized using a high-throughput slide scanner and were processed using Biospective's PERMITSTM software platform.

To navigate though this Image Story, you can use the arrows and/or the Table of Contents icon in the upper right corner of this panel.

Navigation Panel with Tooltips

You can also interact with the microscopy image in the viewer on the right at any time to further explore this high-resolution data.

Phosphorylated Human Tau Pathology

This microscopy image shows AT8 immunostaining for pTau. The ipsilateral (left hemisphere) midbrain shows extensive staining in the vicinity of the SNc and slightly beyond. For anatomical reference, an illustration with atlas labels for this brain level is provided below.

Coronal Brain Atlas at the Level of the Substantia Nigra

Coronal Mouse Brain Section (Bregma -3.2) with Neuroanatomy Labels

Tau Pathology in Neuronal Cell Bodies & Processes

This high magnification image shows extensive pTau staining in both the soma and processes of neurons in the SNc.

Neurodegeneration in the Substantia Nigra

As can be seen in this microscopy image, there is substantial loss of TH-positive dopaminergic neurons in the ipsilateral SNc compared to the contralateral hemisphere. For reference, an illustration with atlas labels for this brain level is provided below.

Coronal Mouse Brain Section (Bregma -3.2) with Neuroanatomy Labels

Using our PERMITSTM quantitative analysis software, we have quantified the TH staining in the SNc. The plot below shows a highly significant reduction in the ipsilateral hemisphere of the AAV-Tau compared to the AAV-null (control) mice.

Tyrosine Hydroxylase Staining in the Substantia Nigra

TH stain density for AAV-Tau compared to AAV-null (control) injections; mean ± SEM, t-test, **** p<0.0001.

Brain Atrophy in the SNc and Midbrain

Regional brain atrophy is a key feature of tauopathies. Magnetic Resonance Imaging (MRI) is clinically used for non-invasive neuroimaging of Progressive Supranuclear Palsy (see our Resource) and Corticobasal Degeneration (see our Resource). Our team at Biospective has investigated the spatiotemporal pattern of brain atrophy in tauopathies (see MRI Measures of Disease Progression for Progressive Supranuclear Palsy Clinical Trials and MRI & Corticobasal Degeneration). We have found significant atrophy in multiple brain areas, including the midbrain and striatum in both diseases.

Given that MRI is a “translational biomarker”, we have acquired high-resolution in vivo anatomical 3D MR images from the AAV-hTau and AAV-null (control) mice using a 7T preclinical MRI scanner. We performed fully-automated image processing using our proprietary NIGHTWINGTM software and found highly significant brain atrophy in the SNc and midbrain. This data corresponds nicely to the loss of TH-positive neurons seen in the microscopy image.

MRI Brain Atlas and Volume Data for the SNc Level

Anatomical MRI with segmented SNc and midbrain, as well as plots of relative difference between ipsilateral and contralateral hemispheres for AAV-Tau compared to AAV-null (control) injections; mean ± SEM, t-test, **** p<0.0001.

Dopaminergic Neurons in the Contralateral SNc

This microscopy image shows the contralateral (right hemisphere) SNc which demonstrates TH-positive cell bodies and processes in red. The nuclei of the dopaminergic neurons are shown in blue.

Loss of Dopaminergic Neurons in the Ipsilateral SNc

This microscopy image shows the ipsilateral (left hemisphere) SNc which demonstrates a profound reduction of TH-positive cell bodies and processes (in red) compared to the contralateral hemisphere. The dopaminergic neuron nuclei are shown in blue.

Neurodegeneration in the Caudate-Putamen & Dopaminergic Motor Deficits

This microscopy image shows severe dopaminergic denervation of the ipsilateral (left hemisphere) caudate-putamen (loss of TH-positive terminals). For reference, an illustration with atlas labels for this approximate brain level is provided below.

Atlas Section at the Striatum Level

Coronal Mouse Brain Section (Bregma +0.86) with Neuroanatomy Labels

Using our PERMITSTM quantitative analysis software, we have quantified the TH staining in the Caudate-Putamen. The plot below shows a highly significant reduction in the ipsilateral hemisphere.

Tyrosine Hydroxylase Staining in the Caudate-Putamen

TH stain density for AAV-Tau compared to AAV-null (control) injections; mean ± SEM, t-test, **** p<0.0001.

This loss of dopaminergic innervation corresponds well with unilateral motor deficits in these mice, including a highly significant increase in use of the ipsilateral paw during the Cylinder Test, decreased latency to fall in the Rotarod Test, increased swings to the contralateral side in the Tail Suspension Swing Test (TSST), and increased Hindlimb Clasping.

Illustration of Motor Tests and Plots of AAV-Tau vs. AAV-null

Cylinder Test, Rotarod Test, Tail Swing Suspension Test (TSST), and Hindlimb Clasping data for AAV-Tau compared to AAV-null (control) injections; mean ± SEM, t-test, **** p<0.0001.

Loss of Dopaminergic Terminals in the Ipsilateral Caudate-Putamen

This high magnification view shows the severe extent of loss of dopaminergic (TH-positive) terminals in the ipsilateral striatum. There are some remaining (albeit dystrophic) axons present.

We have also identified significant brain atrophy in the caudate-putamen on MRI scans, which aligns well with our analysis of human MRI data from Progressive Supranuclear Palsy and Corticobasal Degeneration populations. This data supports the “translatability” of this tauopathy model.

MRI Atlas and Volume Data at Striatum Level

Anatomical MRI with segmented striatum, as well as plot of relative difference between ipsilateral and contralateral striatum. ****p<0.0001.

Microgliosis in Response to Human 2N4R Tau Expression

In this low magnification image, one can readily appreciate the higher density of Iba-1-positive microglia in the ipsilateral (left) hemisphere (indicated by the box) relative to the contralateral hemisphere.

The plot below shows the Iba-1 stain density in the SNc.

Plots of Iba-1 staining for AAV-Null and AAV-Tau Injected Mice

Iba-1 stain density for AAV-Tau compared to AAV-null (control) injections; mean ± SEM, t-test, *** p<0.001.

We have performed a morphological analysis of microglia using a novel computer vision & machine learning approach developed by our team. This fully-automated algorithm classifies non-activated (ramified) and activated (non-ramified) microglia.

Image of non-activated and activated microglia

The plot below shows the microglial activation in the SNc, with highly significant increased microglial activation in the AAV-Tau mice.

Plot of PERMITS Data Showing Activated Microglia in SNc

Microglial activation for AAV-Tau compared to AAV-null (control) injections; mean ± SEM, t-test, *** p<0.0001.

Iba-1 Staining in Proximity to Phosphorylated Tau

This high magnification view shows the increased density of Iba-1-stained microglia in areas with phosphorylated tau aggregates.

Astrogliosis & Human Tau Pathology

This low magnification microscopy image show a higher density of GFAP-positive astrocytes in the ipsilateral hemisphere (indicated by the box). The plot below shows the GFAP stain density in the SNc.

Plot of GFAP Staining Density in SNc

GFAP stain density for AAV-Tau compared to AAV-null (control) injections; mean ± SEM, t-test, **** p<0.0001.

GFAP Staining in Proximity to p-Tau

This high magnification view shows the increased density of GFAP-stained astrocytes in areas with phosphorylated Tau aggregates.

Summary

This novel mouse model of tauopathies with Parkinsonian features recapitulates many of the hallmark features of Progressive Supranuclear Palsy and Corticobasal Degeneration, including the development of asymmetric motor dysfunction (due to unilateral injection), and associated loss of TH+ SNc neurons and striatal TH expression.

AAV-hTau regionally results in highly significant brain atrophy, elevated microglial density and activation levels, and increased astrocyte density and hypertrophy. Further studies are planned to continue to investigate the pathologic changes in this model.

This inducible and rapidly progressing mouse model is well-suited for drug discovery with quantitative in vivo and ex vivo readouts, and possesses distinct advantages over existing transgenic models as a screening method for novel treatment options targeting tau-related pathology.

Please feel free to further explore the microscopy image in the viewer.

We would be happy to discuss this model and our characterization if you would like to Contact Us.

Table of Contents
Control Panel
Section: SNc Section 1
Channels

Learn more about our characterization of our AAV-Tau mouse models, our validated measures, and our Preclinical Neuroscience CRO services.

Discover more of our Alzheimer's Disease & Tauopathies Models

FAQs

Can MRI brain atrophy be used as a translational biomarker?


Is brain atrophy primarily driven by tau or amyloid-β?


Can you quantitatively assess dopaminergic denervation of the caudate-putamen in this tauopathy model?


What is the "tail suspension swing test"?


How do you quantify "reactive" astrocytes in the AAV-Tau model?


What is an "adeno-associated virus" (AAV) vector?


Related Content

Up-to-date information on Alzheimer's Disease & Tauopathies and best practices related to the use of translational biomarkers for the evaluation of therapeutic agents in animal models.

More Information

Let us know what you’re interested in. Our team will be happy to discuss with you!

Email us at i[email protected] or simply complete & submit the form below. 

Name*
Email*
Phone Number*
Affiliation (Company/University)*
Message*

Your privacy is important to us. We will protect your data as outlined in our Privacy Notice.

I agree to the terms in the Privacy Notice*

We use necessary cookies to make our site work. We also use other cookies to help us make improvements by measuring how you use the site or for marketing purposes. You have the choice to accept or reject them all. For more detailed information about the cookies we use, see our Privacy Notice.